台股 » 個股 » 生華科 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生華科

(6492)
可現股當沖
  • 股價
    42.80
  • 漲跌
    ▲0.50
  • 漲幅
    +1.18%
  • 成交量
    122
  • 產業
    上櫃 生技醫療類股▲0.14%
  • 154人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
生華科 (6492)籌碼相關-元大-板橋三民 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

元大-板橋三民 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/1600.00242.1542.35-2378-0.53%
2025/01/1500.00142.2042.15-1381-0.26%
2025/01/10144.55343.9543.35-2387-0.52%
2025/01/0200.00343.0042.90-3405-0.74%
2024/12/3100.00342.8243.50-3410-0.73%
2024/12/3000.00243.3843.00-2418-0.48%
2024/12/2500.00242.5042.60-2441-0.45%
2024/12/2400.00143.0042.55-1450-0.22%
2024/12/1900.00142.2042.50-1484-0.21%
2024/12/1300.00542.3042.35-5587-0.85%
2024/12/1200.00143.3542.95-1591-0.17%
2024/12/1100.00243.1043.10-2592-0.34%
2024/12/0400.00545.6045.35-5620-0.81%
2024/12/02145.30345.2745.40-2634-0.32%
2024/11/27444.5400.0044.2046550.61%
2024/11/22245.4000.0045.3526690.30%
2024/11/21545.1000.0045.6556710.74%
2024/11/20145.75145.2045.1006820.00%
2024/11/18145.0000.0044.1016990.14%
2024/11/12347.2800.0047.3537260.41%
2024/11/06249.5000.0049.3527460.27%
2024/10/30151.502151.3250.50-20777-2.57%
2024/10/291053.9300.0052.10107721.29%
2024/10/281058.0000.0052.60107561.32%
2024/10/25352.03553.0854.40-2645-0.31%
2024/10/21250.5000.0049.9026600.30%
2024/10/15150.80150.3050.1001,0550.00%
2024/10/0900.00249.0049.15-21,059-0.19%
2024/10/0800.00250.7050.80-21,052-0.19%
2024/09/2700.00154.0054.70-11,035-0.10%
2024/09/26152.5000.0051.9011,0230.10%
2024/09/20753.941054.3555.00-31,023-0.29%
2024/09/19555.40755.9753.20-2995-0.20%
2024/09/1800.00252.3052.30-2943-0.21%
2024/09/16347.40247.4847.6019430.11%
2024/09/12047.0000.0047.3009790.00%
2024/09/09248.43147.8548.2011,0340.10%
2024/09/0600.00346.7046.55-31,023-0.29%
2024/09/04249.5000.0047.8521,0170.20%
2024/09/0300.00251.5051.40-21,007-0.20%
2024/09/0200.00151.0050.70-11,003-0.10%
2024/08/29250.7500.0050.0029930.20%
2024/08/28149.75450.0350.30-3981-0.31%
2024/08/27549.19250.0049.0039730.31%
2024/08/2600.00550.2849.65-5971-0.51%
2024/08/23349.1700.0049.3539660.31%
2024/08/22349.5300.0049.8039620.31%
2024/08/21451.00251.2050.6029480.21%
2024/08/20249.63751.0450.90-5943-0.53%
2024/08/19049.6500.0049.8009300.00%
2024/08/16149.3000.0050.1019280.11%
2024/08/15147.40149.8049.6009170.00%
2024/08/12148.70148.3048.1508850.00%
2024/08/09348.82548.4048.15-2879-0.23%
2024/08/08149.30149.9049.7508650.00%
2024/08/07950.65351.3050.7068560.70%
2024/08/0600.00250.0049.00-2841-0.24%
2024/08/05147.7000.0047.7018180.12%
2024/08/01155.3000.0055.4018040.12%
2024/07/31156.5000.0056.5017990.13%
2024/07/290.156.8000.0056.900.17880.01%
2024/07/191060.88959.2058.1017350.14%
2024/07/181160.651262.4162.20-1658-0.15%
2024/07/17259.45159.5058.9015430.18%
2024/07/1600.00756.6957.20-7427-1.64%
2024/07/09143.4000.0043.4013190.31%
2024/07/0200.00245.4845.50-2307-0.65%
2024/06/2800.00247.1547.10-2299-0.67%
2024/06/26448.93149.0048.7532881.04%
2024/06/21147.25246.8345.20-1258-0.39%
2024/06/2000.00147.7047.60-1250-0.40%
2024/06/19645.9000.0047.9562242.67%
2024/06/17345.1800.0045.3531871.60%
2024/05/2000.00242.0541.95-2174-1.15%
2024/05/16141.7000.0041.7011770.56%
2024/05/0700.00141.2041.25-1180-0.55%
2024/04/2600.00240.6040.70-2182-1.09%
2024/04/1700.00242.0041.75-2183-1.09%
2024/04/09144.1000.0043.5511910.52%
2024/04/08144.2000.0044.2011910.52%
2024/04/03243.10243.1043.1001910.00%
2024/03/29644.13244.4044.1041982.02%
2024/03/2800.00343.4243.40-3199-1.51%
2024/03/25544.8100.0044.5052012.48%
2024/03/21243.1800.0042.7022001.00%
2024/03/12143.6000.0043.6012140.47%
2024/03/1100.00142.6042.65-1223-0.45%
2024/03/0600.00543.6443.40-5331-1.51%
2024/03/0400.00443.6443.60-4339-1.18%
2024/03/0100.00244.2544.25-2344-0.58%
2024/02/29245.0000.0044.8523660.55%
2024/02/2600.00345.5845.80-3379-0.79%
2024/02/22345.60345.6045.2503980.00%
2024/02/21445.93545.7845.80-1406-0.25%
2024/02/20047.5500.0045.7004110.00%
2024/02/19347.0200.0046.5534170.72%
2024/02/15546.10346.4346.0024360.46%
2024/02/05446.91346.2246.1514450.22%
生華科新藥再獲孤兒藥資格 上市可獲7年市場獨賣保護期Anue鉅亨-2024/10/25
上櫃「肥貓」董監現形 台嘉碩、大宇資、穩懋、生華科為前四肥Anue鉅亨-2024/04/15
生華科治療新冠、流感等泛病毒感染新藥 將啟動二期臨床Anue鉅亨-2023/11/21
生華科 相關文章
生華科 相關影音